Cel Sci Corp (New York Stock Exchange Arca:CVM)
| Market Cap | $21.28M-80.7% |
| Revenue (ttm) | $0 |
| Net Income | -$22.70M+10.7% |
| EPS | -$2.58+74.2% |
| Shares Out | 17.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 879,700 |
| Open | $1.53 |
| Previous Close | $1.47 |
| Day's Range | $1.19 - $1.59 |
| 52-Week Range | $0.89 - $7.80 |
| Beta | 0.62 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Dec 23, 2026 |
About CVM
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Cel Sci Corp Stock Analysis — InsiderScore
Cel Sci Corp scored higher than 0% of companies evaluated by InsiderBuying, and ranked 101st out of 102 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Cel Sci Corp bought $138.0K of stock across 1 purchase in the last 90 days, the largest of them $138.0K.
The average purchase added about 46% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Dec 23, 2026Earnings report
$CVM stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CVM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CVM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CVM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CVM Revenue by Segment
| Stock-based compensation | $1.35M | 62.42% |
| Public & investor relation costs | $333.00K | 15.41% |
| Legal & accounting fees | $287.00K | 13.28% |
| Supplies & materials | $192.00K | 8.89% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CVM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CVM from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CVM
| VTIVanguard Morningstar Total Stock Market ETF | $496.91K |
| VXFVanguard Extended Market ETF | $154.12K |
| SILXETFMG Prime 2x Daily Junior Silver Miners ETF | $33.48K |
| VALTETFMG Sit Ultra Short ETF | $17.80K |
| GERMETFMG Treatments, Testing and Advancements ETF | $14.65K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $10.00K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CVM’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+8.5 since Sep 23Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
